KR100935092B1 - 난소암의 치료 및 진단용 조성물 및 방법 - Google Patents

난소암의 치료 및 진단용 조성물 및 방법 Download PDF

Info

Publication number
KR100935092B1
KR100935092B1 KR1020037000780A KR20037000780A KR100935092B1 KR 100935092 B1 KR100935092 B1 KR 100935092B1 KR 1020037000780 A KR1020037000780 A KR 1020037000780A KR 20037000780 A KR20037000780 A KR 20037000780A KR 100935092 B1 KR100935092 B1 KR 100935092B1
Authority
KR
South Korea
Prior art keywords
seq
delete delete
amino acid
antigen
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037000780A
Other languages
English (en)
Korean (ko)
Other versions
KR20030022293A (ko
Inventor
밋챰제니퍼엘
킹고든이
앨게이트폴에이
플링스티븐피
레터마크더블유
팽거게리리챠드
리드스티븐지
베드빅토마스에스
카터대릭
힐폴
앨본얼
Original Assignee
코릭사 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/636,801 external-priority patent/US7202334B1/en
Priority claimed from US09/667,857 external-priority patent/US6699664B1/en
Priority claimed from US09/827,271 external-priority patent/US6962980B2/en
Priority claimed from US09/884,441 external-priority patent/US20020119158A1/en
Application filed by 코릭사 코포레이션 filed Critical 코릭사 코포레이션
Publication of KR20030022293A publication Critical patent/KR20030022293A/ko
Application granted granted Critical
Publication of KR100935092B1 publication Critical patent/KR100935092B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020037000780A 2000-07-17 2001-07-17 난소암의 치료 및 진단용 조성물 및 방법 Expired - Fee Related KR100935092B1 (ko)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US61774700A 2000-07-17 2000-07-17
US09/617,747 2000-07-17
US09/636,801 US7202334B1 (en) 1998-12-17 2000-08-10 Compositions and methods for the therapy and diagnosis of ovarian cancer
US09/636,801 2000-08-10
US09/667,857 2000-09-20
US09/667,857 US6699664B1 (en) 1998-12-17 2000-09-20 Compositions and methods for the therapy and diagnosis of ovarian cancer
US09/827,271 2001-04-04
US09/827,271 US6962980B2 (en) 1999-09-24 2001-04-04 Compositions and methods for the therapy and diagnosis of ovarian cancer
US09/884,441 2001-06-18
US09/884,441 US20020119158A1 (en) 1998-12-17 2001-06-18 Compositions and methods for the therapy and diagnosis of ovarian cancer
PCT/US2001/022635 WO2002006317A2 (en) 2000-07-17 2001-07-17 Compositions and methods for the therapy and diagnosis of ovarian cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020087015265A Division KR20080068143A (ko) 2000-07-17 2001-07-17 난소암의 치료 및 진단용 조성물 및 방법

Publications (2)

Publication Number Publication Date
KR20030022293A KR20030022293A (ko) 2003-03-15
KR100935092B1 true KR100935092B1 (ko) 2010-01-08

Family

ID=46395398

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037000780A Expired - Fee Related KR100935092B1 (ko) 2000-07-17 2001-07-17 난소암의 치료 및 진단용 조성물 및 방법

Country Status (3)

Country Link
JP (1) JP4942906B2 (https=)
KR (1) KR100935092B1 (https=)
CY (1) CY1108790T1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202144388A (zh) * 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE413466T1 (de) * 1998-09-02 2008-11-15 Diadexus Inc Verfahren zur diagnose, bewertung sowie bilddarstellung verschiedener krebserkrankungen
US6468546B1 (en) * 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer

Also Published As

Publication number Publication date
CY1108790T1 (el) 2014-04-09
JP2004526406A (ja) 2004-09-02
JP4942906B2 (ja) 2012-05-30
KR20030022293A (ko) 2003-03-15

Similar Documents

Publication Publication Date Title
CN100439395C (zh) 用于治疗和诊断卵巢癌的组合物及方法
US6468546B1 (en) Compositions and methods for therapy and diagnosis of ovarian cancer
US20030091580A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
US20030165504A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
US20030124140A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
US7749505B2 (en) Compositions and methods for the therapy and diagnosis of lung cancer
CZ20012587A3 (cs) Izolovaný protein, nukleová kyselina, virový vektor, farmaceutický prostředek, izolovaná populace T buněk, způsob posílení imunitní odpovědi, způsob odstranění nádorových buněk, způsob stimulace a/nebo namnoľení T buněk a způsob přípravy fúzního proteinu
US6488931B1 (en) Compositions and methods for therapy and diagnosis of ovarian cancer
US20020068288A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
US6670463B1 (en) Compositions and methods for therapy of ovarian cancer
US6699664B1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
US6528253B1 (en) Compositions and methods for diagnosis of ovarian cancer
US20050031634A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
KR100935092B1 (ko) 난소암의 치료 및 진단용 조성물 및 방법
KR100836516B1 (ko) 난소암의 진행을 억제하기 위한 약제학적 조성물 및 백신
EP1319069B1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
HK1121464A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
CN101230100A (zh) 用于治疗和诊断卵巢癌的组合物及方法
ES2329444T3 (es) Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon.
HK1068506A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
US20030170246A1 (en) Lipophilin complexes for use in cancer diagnosis and therapy

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20121225

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20121225